Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

NCT05394233 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer
EGFR Gene Mutation

Interventions

DRUG: Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed

Sponsor

Sichuan Cancer Hospital and Research Institute